Bedaquiline
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| - | Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref> Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref><ref name="a5">[https://web.archive.org/web/20180820052256/http://www.who.int/tb/publications/2018/rapid_communications_MDR/en/ "WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)".] WHO. Archived from the original on 20 August 2018. Retrieved 24 April 2019.</ref><ref name="a6">PMID: | + | Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref> Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis.<ref name="a1">[https://www.drugs.com/monograph/bedaquiline.html "Bedaquiline Fumarate".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref><ref name="a5">[https://web.archive.org/web/20180820052256/http://www.who.int/tb/publications/2018/rapid_communications_MDR/en/ "WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)".] WHO. Archived from the original on 20 August 2018. Retrieved 24 April 2019.</ref><ref name="a6">PMID:30215381</ref> See also [https://en.wikipedia.org/wiki/Bedaquiline Bedaquiline]. |
[[4v1f]]. | [[4v1f]]. | ||
Revision as of 12:34, 28 December 2023
| |||||||||||
References
- ↑ 1.0 1.1 "Bedaquiline Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ↑ "WHO Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)". WHO. Archived from the original on 20 August 2018. Retrieved 24 April 2019.
- ↑ Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 Sep 8;392(10150):821-834. PMID:30215381 doi:10.1016/S0140-6736(18)31644-1
